Population pharmacokinetics of a novel PCSK9 antisense oligonucleotideBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32024-03-192OA
A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase IICPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32022-10-016OAAI
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trialCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82022-08-207OAAI
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT intervalBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32022-06-1010OAAI
An oral antisense oligonucleotide for PCSK9 inhibitionSCIENCE TRANSLATIONAL MEDICINEIF14.62021-05-1289PRE
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose StudyCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82019-10-3023OAAI
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulatorBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32018-04-2217OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向